Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 22/11/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Respiratory Tract Infections;Cystic Fibrosis, Date of authorisation: 18/02/2019, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): LysaKare, arginine,lysine, Radiation Injuries, Date of authorisation: 25/07/2019, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Amyloidosis, Date of authorisation: 16/11/2011, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Opfolda, miglustat, Glycogen Storage Disease Type II, Date of authorisation: 26/06/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Scemblix, asciminib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 25/08/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Levetiracetam Sun, levetiracetam, Epilepsy, Date of authorisation: 14/12/2011, Revision: 19, Status: Authorised

Union Product Database – Product grouping and 3rd country product names Webinar for UPD Industry users, Online, 14:00 - 15:00 Amsterdam time (CEST), from 18/09/2023 to 18/09/2023

Human medicines European public assessment report (EPAR): Vaxneuvance, pneumococcal polysaccharide conjugate vaccine (adsorbed), Pneumococcal Infections, Date of authorisation: 13/12/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Carcinoma, Hepatocellular, Date of authorisation: 20/02/2023, Revision: 2, Status: Authorised